Skip to main content

Avanir Pharmaceuticals Inc (NASDAQ:AVNR) Investor Investigation Over Potential Securities Laws Violations

  • If you purchased shares of Avanir Pharmaceuticals Inc (NASDAQ:AVNR), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Site Members can sign up for company wide alerts

Investigation Overview

December 17, 2013 (Update) -- On December 10, 2013, Avanir Pharmaceuticals Inc reported financial results for the three and twelve-months ended September 30, 2013 and announced results for phase II PRIME Study. Avanir Pharmaceuticals said that PRIME, its phase II clinical trial of the investigational drug AVP-923 (dextromethorphan / quinidine) for the treatment of central neuropathic ...



You must register (for free) or login to view the entire investigation.